Novartis
Study Title: A Randomized, Placebo-controlled, Parallel Group, 72-week Study to Evaluate the Efficacy and Safety of VHB937 in Participants With Early Alzheimer's Disease Followed by an Extension (Novartis Study)
Purpose
The Novartis study seeks adults aged 50 to 85 to participate in a clinical trial evaluating whether VHB937 is safe and beneficial in people with early Alzheimer’s disease (AD). The study will assess the safety of VHB937 and its effects on memory and other cognitive abilities, daily activities, and brain changes. This medication targets neuroimmune pathways in early AD. The study will involve approximately 407 participants from research sites across 15 countries. UCLA aims to recruit 7 participants.
Participants will:
- Receive VHB937 or placebo via intravenous infusions monthly for 1.5 years during the double-blind period
- Participants who are enrolled in Part 1 will be randomly assigned study drug or placebo at a 4:1 ratio
- Participants who are enrolled in Part 2 will be randomly assigned study drug or placebo at a 2:1 ratio
- Receive VBH937 via intravenous infusions monthly for up to 6 years during the open-label extension period
- Undergo various research assessments, including medical history review, physical and neurological examinations, blood draws, memory tests, and brain scans.
- Need to have a study partner (i.e., relative, friend, caregiver) to accompany the participant for study visits.
(PI: Marie Kim, MD, PhD, Easton Center's Katherine and Benjamin Kagan Alzheimer's Disease Treatment Development Program)
Contact: Kagan Clinical Trials Program at (310) 794-6191 or send an email to EastonClinicalTrials@mednet.ucla.edu to participate in this study or for more information.
More information on the Novartis Study is available at clinicaltrials.gov ID#: NCT07094516.